49 Results

People

  1. Landau
    Landau
  2. Giralt
    Giralt
  3. Chung
    Chung
  4. Hassoun
    Hassoun
  5. Lesokhin
    Lesokhin
  6. Shah
    Shah
  7. Korde
    Korde
  8. Mailankody
    Mailankody
  9. Scordo
    Scordo
  10. Shah
    Shah

Groups

  1. Bone Marrow Transplant (49)
  2. Center for Hematologic Malignancies (49)
  3. Department of Medicine (49)
  4. Hematologic Malignancies Research (49)
  5. Hematologic Malignancies, Division of (49)
  6. Survivorship Research (49)
  7. Myeloma (48)
  8. CTCR Scholars (33)
  9. Epidemiology and Biostatistics (31)
  10. Biostatistics Service (30)
  1. "Hematologic Malignancies Research"
  2. "Heather Landau"
  3. "Elsevier Inc."
Formats
  1. Meeting Abstract (40)
  2. Journal Article (8)
  3. Research Letter (1)
Groups
  1. Bone Marrow Transplant (49)
  2. Center for Hematologic Malignancies (49)
  3. Department of Medicine (49)
  4. Hematologic Malignancies Research (49)
  5. Hematologic Malignancies, Division of (49)
  6. Survivorship Research (49)

More Groups

People
  1. Heather Landau (49)
  2. David Chung (48)
  3. Sergio Giralt (47)
  4. Alexander Lesokhin (44)
  5. Hani Hassoun (44)
  6. Gunjan Shah (37)

More People

Years
  1. 2023 (13)
  2. 2022 (9)
  3. 2021 (2)
  4. 2020 (6)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (29)
  2. Biology of Blood and Marrow Transplantation (17)
  3. Clinical Biochemistry (1)
  4. Transplantation and Cellular Therapy (1)
  5. eClinicalMedicine (1)
Publishers
  1. Elsevier Inc. (49)

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save